Survanta Related Published Studies
Well-designed clinical trials related to Survanta (Beractant)
Comparison of Infasurf (calfactant) and Survanta (beractant) in the prevention and treatment of respiratory distress syndrome. [2005.08]
A randomized trial comparing beractant and poractant treatment in neonatal respiratory distress syndrome. [2005.06]
A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants. [2005.04]
Randomized trial comparing two natural surfactants (Survanta vs. bLES) for treatment of neonatal respiratory distress syndrome. [2005.01]
A randomized, multicenter masked comparison trial of poractant alfa (Curosurf) versus beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants. [2004.04]
Early administration of the second dose of surfactant (beractant) in the treatment of severe hyaline membrane disease. [2001.03]
Serial phospholipid analysis in preterm infants: comparison of Exosurf and Survanta. [1999.03]
Multicenter study of surfactant (beractant) use in the treatment of term infants with severe respiratory failure. Survanta in Term Infants Study Group. [1998.01]
Comparative efficacy of exosurf and survanta surfactants on early clinical course of respiratory distress syndrome and complications of prematurity. [1997.11]
Comparison of Infasurf (calf lung surfactant extract) to Survanta (Beractant) in the treatment and prevention of respiratory distress syndrome. [1997.07]
Exosurf versus Survanta surfactant preparations: proportional-hazards regression analysis of time to successful extubation and discontinuation of oxygen therapy. [1996.01]
Surfactant (beractant) therapy for infants with congenital diaphragmatic hernia on ECMO: evidence of persistent surfactant deficiency. [1994.03]
Modified bovine surfactant (Survanta) versus a protein-free surfactant (Exosurf) in the treatment of respiratory distress syndrome in preterm infants: a pilot study. [1994.01]
Multicenter trial of single-dose modified bovine surfactant extract (Survanta) for prevention of respiratory distress syndrome. Ross Collaborative Surfactant Prevention Study Group. [1990.06]
Well-designed clinical trials possibly related to Survanta (Beractant)
Early intratracheal instillation of budesonide using surfactant as a vehicle to prevent chronic lung disease in preterm infants: a pilot study. [2008.05]
One-year follow-up of very preterm infants who received lucinactant for prevention of respiratory distress syndrome: results from 2 multicenter randomized, controlled trials. [2007.06]
One-Year Follow-up of Very Preterm Infants Who Received Lucinactant for Prevention of Respiratory Distress Syndrome: Results From 2 Multicenter Randomized, Controlled Trials. [2007.05.28]
Surfactant administration by transient intubation in infants 29 to 35 weeks' gestation with respiratory distress syndrome decreases the likelihood of later mechanical ventilation: a randomized controlled trial. [2005.11]
[Treatment of hyaline membrane disease in the preterm newborn with exogenous lung surfactant: a controlled study] [2005.07]
Immediate changes in lung compliance following natural surfactant administration in premature infants with respiratory distress syndrome: a controlled trial. [2004.10]
A comparison of efficacy between two natural exogenous surfactant preparations in premature infants with respiratory distress syndrome. [2004.07]
Early surfactant for neonates with mild to moderate respiratory distress syndrome: a multicenter, randomized trial. [2004.06]
Randomized clinical trial comparing two natural surfactant preparations to treat respiratory distress syndrome. [2004.03]
Comparison of three treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome. [2003.07]
Exogenous surfactant supplementation in infants with respiratory syncytial virus bronchiolitis. [2000.10]
Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome. [2000]
Randomized trial of permissive hypercapnia in preterm infants. [1999.11]
Comparative trial of artificial and natural surfactants in the treatment of respiratory distress syndrome of prematurity: experiences in a developing country. [1999.05]
Surfactant lavage for meconium aspiration syndrome: a pilot study. [1999.05]
Prevention of chronic lung disease in preterm infants by early postnatal dexamethasone therapy. [1999.01]
Changes in pulmonary artery pressure during the acute phase of respiratory distress syndrome treated with three different types of surfactant. [1998.03]
Bovine surfactant therapy for patients with acute respiratory distress syndrome. [1997.04]
Effects of early indomethacin administration on oxygenation and surfactant requirement in low birth weight infants. [1997.02]
Comparison of the changes in the a/A oxygen ratio after administration of two surfactants for the treatment of neonatal respiratory distress syndrome. [1997.02]
Surfactant replacement therapy for meconium aspiration syndrome. [1996.01]
Pharmacokinetics of bovine surfactant in neonatal respiratory distress syndrome. [1995.09]
Partial liquid ventilation in premature lambs with respiratory distress syndrome: efficacy and compatibility with exogenous surfactant. [1995.03]
Randomised clinical trial of two treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome. [1995.01]
[Pulmonary surfactant and its clinical application] [1994.12]
Cardiorespiratory and stress hormone responses during first dose surfactant administration in neonates with RDS. [1994.04]
A multicenter randomized trial comparing two surfactants for the treatment of neonatal respiratory distress syndrome. National Institute of Child Health and Human Development Neonatal Research Network. [1993.11]
Pulmonary follow-up 2.5 years after a randomized, controlled, multiple dose bovine surfactant study of preterm newborn infants. [1993.03]
Comparison of three dosing procedures for administration of bovine surfactant to neonates with respiratory distress syndrome. [1993.03]
Improved pulmonary outcome after exogenous surfactant therapy for respiratory failure in term infants requiring extracorporeal membrane oxygenation. [1993.02]
Ductal patency in neonates with respiratory distress syndrome. A randomized surfactant trial. [1991.09]
Reduction of neonatal mortality after multiple doses of bovine surfactant in low birth weight neonates with respiratory distress syndrome. [1991.07]
Improved neonatal survival following multiple doses of bovine surfactant in very premature neonates at risk for respiratory distress syndrome. [1991.07]
A European multicenter randomized controlled trial of single dose surfactant therapy for idiopathic respiratory distress syndrome. [1990.03]
Other research related to Survanta (Beractant)
Comparison of beractant and calfactant in a neonatal intensive care unit. [2004.02.01]
Acute effects on systemic circulation after intratracheal instillation of Curosurf or Survanta in surfactant-depleted newborn piglets. [1998.03]
Spiking Survanta with synthetic surfactant peptides improves oxygenation in surfactant-deficient rats. [1997.09]
Cost effectiveness of beractant in the prevention of respiratory distress syndrome. [1993.10]
Physiologic responses and distribution of aerosolized surfactant (Survanta) in a nonuniform pattern of lung injury. [1993.06]
Comparison of a phospholipid-based protein-free surfactant and a natural bovine surfactant (SURVANTA) during pressure and volume-controlled ventilation in an improved rabbit fetus model. [1993.03]
Treatment Investigational New Drug experience with Survanta (beractant). [1993.03]
Surface tension of therapeutic surfactants (exosurf neonatal, infasurf, and survanta) as evaluated by standard methods and criteria. [1992.09]
Failure to detect surfactant protein-specific antibodies in sera of premature infants treated with survanta, a modified bovine surfactant. [1991.04]
Other possibly related research studies
Polyethylene glycol-surfactant for lavage lung injury in rats. [2005.11]
Dose response to rhCC10-augmented surfactant therapy in a lamb model of infant respiratory distress syndrome: physiological, inflammatory, and kinetic profiles. [2005.12]
Airway lavage with exogenous surfactant in an animal model of meconium aspiration syndrome. [2005.06]
Complement 4 levels as early predictors of poor response to surfactant therapy in respiratory distress syndrome. [2005.04]
Therapeutic effect of surfactant protein D in allergic inflammation of mite-sensitized mice. [2005.04]
Dextran or polyethylene glycol added to curosurf for treatment of meconium lung injury in rats. [2005]
Influence of modified natural and synthetic surfactant preparations on bacterial killing by polymorphonuclear leucocytes. [2004]
Pulmonary function after surfactant lung lavage followed by surfactant administration in infants with severe meconium aspiration syndrome. [2004.08]
Efficacy of three treatment schedules in severe meconium aspiration syndrome. [2004.01]
The laryngeal mask airway for administration of surfactant in two neonates with respiratory distress syndrome. [2004.02]
The use of surfactant in children with acute respiratory distress syndrome: efficacy in terms of oxygenation, ventilation and mortality. [2003]
Surfactant therapy in neonates with respiratory failure due to haemorrhagic pulmonary oedema. [2003.10]
Cardiocirculatory effects of patent ductus arteriosus in extremely low-birth-weight infants with respiratory distress syndrome. [2003.06]
Safety and efficacy of intratracheal recombinant human Clara cell protein in a newborn piglet model of acute lung injury. [2003.10]
Meconium aspiration injury: Uncoupling between the in vivo physiologic and in vitro inflammatory responses. [2001.01]
Effects of exogenous surfactant supplementation and partial liquid ventilation on acute lung injury induced by wood smoke inhalation in newborn piglets. [2003.04]
Effect of exogenous surfactant on the development of surfactant synthesis in premature rabbit lung. [2003.04]
Lung toxicity of paraquat in the rat. [2000.08.11]
Effect of exogenous surfactant on ventilatory and clearance function of the rat's eustachian tube. [2003.01]
Surfactant with SP-B and SP-C analogues improves lung function in surfactant-deficient rats. [2002]
Respiratory distress syndrome in Curacao. Conventional versus surfactant treatment. [2002.06]
Development of chronic lung disease in preterm infants treated with surfactant. [2002.10]
Effect of surfactant on pharyngeal mechanics in sleeping humans: implications for sleep apnoea. [2002.08]
Methylprednisolone does not enhance the surfactant effects on oxygenation and histology in paraquat-induced rat lung injury. [2002.08]
[An effectiveness of surfactant lung lavage (SLL) in meconium aspiration syndrome (MAS)] [2002]
Intratracheal administration of glucocorticoids using surfactant as a vehicle. [2002.08]
Injury responses to different surfactants in ventilated premature lamb lungs. [2002.06]
Functional residual capacity (FRC) does not predict response to surfactant in preterm infants. [2002.04]
The use of inhaled glucocorticosteroids and recovery from adrenal suppression after systemic steroid use in a VLBW premature infant with BPD: case report and literature discussion. [2000.12]
Acute hyperoxic lung injury does not impede adenoviral-mediated alveolar gene transfer. [2002.02.15]
Effects of exogenous surfactant on gas exchange and compliance in rabbits after meconium aspiration. [2002.02]
A comparison of the outcomes of neonates treated with two different natural surfactants. [2001.12]
Identification and quantification of ureaplasmas colonizing the respiratory tract and assessment of their role in the development of chronic lung disease in preterm infants. [2001.09]
Surfactant and corticosteroid effects on lung function in a rat model of acute lung injury. [2001.11]
Resistance of different surfactant preparations to inactivation by meconium. [2001.07]
A rat lung model of instilled liquid transport in the pulmonary airways. [2001.05]
Ultrastructure of exogenous surfactants using cryogenic scanning electron microscopy. [2001.01]
Cerebral hemodynamics after exogenous surfactant administration for respiratory distress syndrome in piglet model. [2000]
Analysis of dynamic surface properties of therapeutic surfactants and lung phospholipids. [2000.10]
Surfactant treatment of neonates with respiratory failure and group B streptococcal infection. Members of the Collaborative European Multicenter Study Group. [2000.11]
Treatment with exogenous surfactant stimulates endogenous surfactant synthesis in premature infants with respiratory distress syndrome. [2000.10]
The effectiveness of surfactant replacement therapy for preterm infants with respiratory distress syndrome. [1998.12]
Calfactant: a review of its use in neonatal respiratory distress syndrome. [1999.07]
Polymer-surfactant treatment of meconium-induced acute lung injury. [2000.08]
|
